Business Standard

Glenmark Pharma hits four-year high, surges 10% in two days

The company has entered into an agreement with Forest Labs to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Related News

Glenmark Pharmaceuticals has rallied over 5% to Rs 547, its highest level since September 2008, with heavy volumes on the NSE. The stock opened at Rs 522 and has seen a combined 1.28 million shares changing hands on the counter so far compared to less than one million shares that were traded daily in past two weeks.

The stock has outperformed the market by surging 10% in past two trading sessions compared to 1% rise in benchmark Sensex after the company informed the stock exchanges that it has entered into an agreement with (Forest Labs) to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Under the terms of agreement, Forest Labs will make a $6-million up-front payment and provide an additional $3 million to support the next phase of work. Forest Labs will make other future payments in FY2014 to support the ongoing mPGES-1 inhibitors programme.

Analyst at Sharekhan recommended a BUY on the stock with the revised target price of Rs 600 saying that it an important development for the company having positive repercussions in the long term.

Read more on:   
|
|

Read More

Two entities fail to make prima facie case to revoke ban: Sebi

The Securities and Exchange Board of India (Sebi) today said the restraining order on two entities, related to plunge in some mid-cap stocks in July, ...

Quick Links

 

Market News

Punj Lloyd up 5% on talk of stake sale in Medanta Medicity

Meanwhile, the board is schedule to meet tomorrow to consider private placement of non convertible debentures, subordinated debt instruments and ...

Soyabean down 1% on weak global cues

Market analysts attributed fall in soyabean prices at futures trade to offloading of positions by speculators, tracking a weak trend overseas

Barley up 1% on low-level buying in spot markets

Marketmen said besides emergence of low-level demand in the spot markets, restricted supplies from growing regions, mainly supported the uptrend

Vikas GlobalOne surges 19% on bonus issue plan

The board will meet on September 17, to consider issue bonus shares to the equity shareholders of the company.

Refined soya oil moves up 0.9% on strong demand

Analysts said fresh positions built-up by speculators on the back of strong demand in spot markets against tight supplies from producing ...

Back to Top